MiMedx Earnings Estimate

MDXG Stock  USD 9.16  0.28  2.97%   
By analyzing MiMedx's earnings estimates, investors can diagnose different trends across MiMedx's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for MiMedx Group is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
MiMedx is projected to generate 0.07125 in earnings per share on the 31st of December 2024. MiMedx earnings estimates show analyst consensus about projected MiMedx Group EPS (Earning Per Share). It derives the highest and the lowest estimates based on MiMedx's historical volatility. Many public companies, such as MiMedx, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing MiMedx's earnings estimates, investors can diagnose different trends across MiMedx's analyst sentiment over time as well as compare current estimates against different timeframes. At this time, MiMedx's Net Profit Margin is most likely to slightly grow in the upcoming years.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

MiMedx Earnings per Share Projection vs Actual

About MiMedx Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of MiMedx earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current MiMedx estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as MiMedx fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-133.7 M-127 M
Retained Earnings Total Equity-145.5 M-138.3 M
Earnings Yield 0.07  0.07 
Price Earnings Ratio 15.15  15.91 
Price Earnings To Growth Ratio(0.05)(0.06)

Currently Active Assets on Macroaxis

When determining whether MiMedx Group is a strong investment it is important to analyze MiMedx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MiMedx's future performance. For an informed investment choice regarding MiMedx Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.1)
Earnings Share
0.59
Revenue Per Share
2.447
Quarterly Revenue Growth
0.029
Return On Assets
0.1838
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.